Phenylarthrite shows a true potentiation of the anti-inflammatory effects of the drugs alone.
Thanks to phenylbutazone, there is a strong inhibition of the action of the enzyme cyclooxygenase (COX-2) in the production of mediators of inflammation. Dexamethasone, on the other hand, inhibits the expression of COX-2, inhibiting the transcription of the relevant gene and, in this way, reduces the generation of prostaglandins responsible for the symptoms of inflammation.
The use of corticosteroid preparations in acute infections should be avoided. When used in non-acute infectious conditions, treatment should be associated with bactericidal antibiotics to the detriment of bacteriostatic antibiotics.
In general, corticosteroids are contraindicated in viral infections and late in pregnancy, when they can induce labor. They should also not be administered to animals that have renal, cardiac and hepatic insufficiency, gastric ulcer and that are hypersensitive to the components of the formula. Its use is not recommended in animals with diabetes mellitus, osteoporosis and hemato cytological alterations (aplastic anemia, leukopenia, agranulocytosis and thrombocytopenia). Do not apply to newborn animals.
Use higher doses for the first 48 hours, then the dose is gradually reduced to a maintenance level and is maintained at a lower level capable of achieving a desired clinical response. Treatment varies from 3 to 14 days (average of 7 days in horses) and 3 days in canines.
There are risks of drug interactions occurring when Phenylbutazone is administered with other non-steroidal anti-inflammatory agents, as they have a similar mechanism of action (cyclooxygenase inhibition) which may increase the occurrence of adverse effects.
Withdrawal period for the Injectable Phenylarthrite product:
Cattle: Slaughter: 14 days. Milk: 05 days.
Pigs: Slaughter: 14 days.
Horses: This product must not be applied to horses intended for slaughter for human consumption.
There are no reviews yet.